Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average cost of $15.34 per share, for a total transaction of $153,400.00. Following the transaction, the director now owns 106,062 shares of the company’s stock, valued at approximately $1,626,991.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Valeant Pharmaceuticals Intl Inc (NYSE VRX) traded up $0.41 during trading hours on Monday, hitting $15.79. The company had a trading volume of 8,381,866 shares, compared to its average volume of 12,850,000. The company has a debt-to-equity ratio of 4.25, a quick ratio of 0.87 and a current ratio of 1.11. Valeant Pharmaceuticals Intl Inc has a 12 month low of $8.31 and a 12 month high of $24.43. The company has a market cap of $5,510.00, a price-to-earnings ratio of 3.88, a price-to-earnings-growth ratio of 0.52 and a beta of -0.28.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.18 billion. During the same period in the previous year, the company posted $1.26 EPS. The firm’s revenue for the quarter was down 10.0% compared to the same quarter last year. sell-side analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.12 EPS for the current fiscal year.
Several research analysts have weighed in on the company. Wells Fargo & Co reissued a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research report on Monday. Deutsche Bank raised Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Monday, March 5th. ValuEngine cut Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. TD Securities lowered their target price on Valeant Pharmaceuticals Intl from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, March 1st. Finally, Piper Jaffray Companies restated a “sell” rating and issued a $10.00 target price (down from $12.00) on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, March 1st. Seven investment analysts have rated the stock with a sell rating, ten have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.30.
ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Director Schutter Richard U. De Acquires 10,000 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/valeant-pharmaceuticals-intl-inc-vrx-director-schutter-richard-u-de-acquires-10000-shares.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.